1. Report Overview

1.1 Global Asthma and COPD Therapies Market Overview

1.2 Global Asthma and COPD Therapies Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Visiongain Reports

1.10 About Visiongain

2. Introduction to Asthma and COPD Therapies

2.1 The Pharmaceutical Industry: A Very Brief Overview

2.2 Classifying Respiratory Diseases: Obstructive and Restrictive

2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive

2.3 What is Asthma?

2.3.1 Trends in Asthma Prevalence

2.3.2 Pathophysiology of Asthma

2.3.3 Symptoms of Asthma

2.3.4 Causes and Triggers for Asthma

2.3.5 Treatment of Asthma

2.3.6 Guidelines for Asthma Treatment

2.3.7 Drug Treatments for Asthma

2.3.8 Drug Delivery Methods in Asthma

2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?

2.4.1 Trends in COPD Prevalence

2.4.2 Pathophysiology of COPD

2.4.3 Signs and Symptoms of COPD

2.4.4 Treatment of COPD

2.4.5 Drug Treatments for COPD

2.4.6 Guidelines for COPD Treatment

2.5 Major Drug Classes in the Treatment of Asthma and COPD

2.5.1 Bronchodilators

2.5.1.1 Beta2-Agonists

2.5.1.2 Anticholinergics

2.5.2 Anti-Inflammatory Drugs

2.5.2.1 Corticosteroids

2.5.2.2 Leukotriene Receptor Antagonists

2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease

2.5.3 Combination Drugs

2.6 Phases of Clinical Trials

2.7 Scope of this Report

3. Asthma and COPD Therapies: Global Market 2019-2029

3.1 The Global Respiratory Drugs Market by Therapeutic Area

3.2 The Global Asthma and COPD Therapies Market in 2018

3.2.1 Leading Asthma and COPD Therapies

3.2.2 Leading Companies in the Asthma and COPD Therapies Market

3.3 Global Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2017-2029

3.3.1 Global Asthma Therapies Market: Sales Forecast, 2017-2029

3.3.2 Global COPD Therapies Market: Sales Forecast 2017-2029

3.4 Global Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2017-2029

3.5 Combination Drugs Lead the Asthma and COPD Therapies Market

3.6 How Will Segmental Shares Change to 2029

3.6.1 Global Asthma and COPD Therapies Market: Drivers and Restraints 2017-2029

3.7 Asthma and COPD Therapies: Trends and Developments

3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers

3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?

4. Bronchodilator Monotherapy Market 2019-2029

4.1 Introduction to Bronchodilator Monotherapy

4.2 The Bronchodilator Monotherapy Market in 2017

4.2.1 Leading Bronchodilators in 2017

4.2.2 Bronchodilator Monotherapy: Market Forecast 2019-2029

4.2.3 How Will Market Shares by Drug Class Change to 2029?

4.3 The Anticholinergics Market 2019-2029

4.3.1 Leading Anticholinergics in 2017

4.3.2 Anticholinergics: Market Forecast 2019-2029

4.3.3 Market Share of Leading Anticholinergics to 2029

4.3.4 Spiriva (tiotropium - Boehringer Ingelheim)

4.3.4.1 Spiriva: Sales Forecast 2019-2029

4.3.4.2 Spiriva: Recent Developments

4.3.5 Atrovent (ipratropium, Boehringer Ingelheim)

4.3.5.1 Atrovent: Sales Forecast 2019-2029

4.3.6 Eklira/Tudorza/Bretaris (alcidinium, AstraZeneca/Menarini)

4.3.6.1 Eklira/Tudorza/Bretaris: Sales Forecast 2017-2029

4.4 The SABAs Market 2019-2029

4.4.1 Leading SABAs in 2017

4.4.2 SABAs: Market Forecast 2019-2029

4.4.3 Market Share of Leading SABAs to 2029

4.4.4 Ventolin (salbutamol, GSK)

4.4.4.1 Ventolin: Sales Forecast 2019-2029

4.4.5 ProAir (salbutamol, Teva)

4.4.5.1 ProAir: Sales Forecast 2019-2029

4.4.6 Proventil (salbutamol, Merck)

4.4.6.1 Proventil: Sales Forecast 2019-2029

4.4.7 Xopenex (levosalbutamol, Dainippon Sumitomo)

4.4.7.1 Xopenex: Sales Forecast 2019-2029

4.5 The Long-Acting Beta2-Agonist (LABA) Market 2017-2029

4.5.1 Leading LABAs in 2017

4.5.2 LABAs: Market Forecast 2019-2029

4.5.3 Market Share of Leading LABAs to 2029

4.5.4 Foradil (formoterol, Merck/Novartis)

4.5.4.1 Foradil: Sales Forecast 2017-2029

4.5.5 Brovana (arfomoterol, Dainippon Sumitomo)

4.5.5.1 Brovana: Sales Forecast 2017-2029

4.5.6 Arcapta/Onbrez (indacaterol, Novartis)

4.5.6.1 Arcapta/Onbrez: Sales Forecast 2017-2029

4.5.7 Serevent (salmeterol, GSK)

4.5.7.1 Serevent: Sales Forecast 2017-2029



5. Anti-inflammatory Drugs Market 2019-2029

5.1 Introduction to Anti-Inflammatory Drugs

5.2 The Anti-Inflammatory Drugs Market in 2017

5.2.1 Leading Anti-Inflammatory Drugs in 2017

5.2.2 Anti-Inflammatory Drugs: Market Forecast 2019-2029

5.2.3 How Will Market Shares by Drug Class Change to 2029?

5.3 The Corticosteroids Market 2019-2029

5.3.1 Leading Corticosteroids in 2017

5.3.2 Corticosteroids: Market Forecast 2019-2029

5.3.3 Market Share of Leading Corticosteroids to 2029

5.3.4 Flixotide/Flovent (fluticasone propionate, GSK)

5.3.4.1 Flixotide/Flovent: Sales Forecast 2019-2029

5.3.5 Pulmicort (budesonide, AstraZeneca)

5.3.5.1 Pulmicort: Sales Forecast 2019-2029

5.3.6 QVAR (beclometasone, Teva)

5.3.6.1 QVAR: Sales Forecast 2017-2029

5.3.7 Asmanex (mometasone, Merck)

5.3.7.1 Asmanex: Sales Forecast 2019-2029

5.4 The Anti-Leukotrienes Market 2019-2029

5.4.1 Leading Anti-Leukotrienes in 2017

5.4.2 Anti-Leukotrienes: Market Forecast 2019-2029

5.4.3 Market Share of Leading Anti-Leukotrienes to 2029

5.4.4 Singulair (montelukast, Merck)

5.4.4.1 Singulair: Sales Forecast 2017-2029

5.5 The Monoclonal Antibodies Market 2019-2029

5.5.1 Monoclonal Antibodies: Market Forecast 2019-2029

5.5.2 Market Share of Leading Monoclonal Antibodies to 2029

5.5.3 Xolair (omalizumab, Novartis/Roche)

5.5.3.1 Xolair: Sales Forecast 2019-2029

5.5.4 Cinquil/Cinquair (reslizumab, Teva)

5.5.4.1 Cinquil: Sales Forecast 2019-2029

5.5.5 Nucala (Mepolizumab, GSK)

5.5.5.1 Nucala: Sales Forecast 2019-2029

5.5.6 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)

5.5.6.1 Benralizumab: Sales Forecast 2019-2029

5.5.7 Lebrikizumab (RG3637, Roche)

5.5.7.1 Lebrikizumab: Sales Forecast 2019-2029

5.5.8 Dupilumab (REGN668, Regeneron/Sanofi)

5.5.8.1 Dupilumab: Sales Forecast 2017-2029

6. Combination Drugs Market 2019-2029

6.1 Introduction to Combination Drugs

6.1.1 Leading Combination Drugs in 2017

6.1.2 Combination Drugs: Market Forecast 2017-2029

6.1.3 How Will Market Shares by Drug Change to 2029?

6.1.4 Advair/Seretide (fluticasone/salmeterol, GSK)

6.1.4.1 Advair/Seretide: Sales Forecast 2017-2029

6.1.5 Symbicort (budesonide/formoterol fumarate, AstraZeneca)

6.1.5.1 Symbicort: Sales Forecast 2017-2029

6.1.5.2 Symbicort: The SMART Concept

6.1.6 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)

6.1.6.1 Combivent: Sales Forecast 2017-2029

6.1.7 Dulera (formoterol/mometasone, Merck)

6.1.7.1 Dulera: Sales Forecast 2017-2029

6.1.8 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)

6.1.8.1 Breo/Relvar: Sales Forecast 2017-2029

6.2 Recently Launched Combination Drugs

7. Leading National Markets 2017-2029

7.1 Regional Breakdown of the Global Asthma and COPD Therapies Market

7.2 Global Asthma and COPD Therapies Market; Regional Forecasts 2017-2029

7.2.1 How Will Regional Market Shares Change to 2029?

7.2.2 National Breakdown of the Global Asthma and COPD Therapies Market

7.2.3 Global Asthma and COPD Therapies Market: National Markets Forecast 2017-2029

7.2.4 How Will National Market Shares Change to 2029?

7.3 The US Asthma and COPD Therapies Market 2017-2029

7.3.1 The US Asthma and COPD Therapies Market Forecast 2017-2029

7.3.2 US Asthma and COPD Therapies Market Trends and Developments

7.3.2.1 Increasing COPD Prevalence in the US

7.3.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence

7.3.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair

7.4 Japanese Asthma and COPD Therapies Market 2017-2029

7.4.1 Japanese Asthma and COPD Therapies Market Forecast 2017-2029

7.4.2 Japanese Asthma and COPD Therapies Market: Trends and Developments

7.4.2.1 Is Generic Penetration to Reach 60% by 2018?

7.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform

7.5 EU5 Asthma and COPD Therapies Market 2017-2029

7.5.1 German Asthma and COPD Therapies Market Forecast 2017-2029

7.5.2 French Asthma and COPD Therapies Market Forecast 2017-2029

7.5.3 UK Asthma and COPD Therapies Market Forecast 2017-2029

7.5.4 Italian Asthma and COPD Therapies Market Forecast 2017-2029

7.5.5 Spanish Asthma and COPD Therapies Market Forecast 2017-2029

7.5.6 EU5 Asthma and COPD Therapies Market: Trends and Developments

7.5.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law

7.5.6.2 France: Social Security Finance Bill 2015

7.5.6.3 UK: Improving Asthma and COPD Patient Outcomes

7.5.6.4 Italy: Austerity Measures Limiting Growth

7.5.6.5 Spain: The Start of Recovery in the Spanish Economy

7.6 BRIC Asthma and COPD Therapies Market 2017-2029

7.6.1 Chinese Asthma and COPD Therapies Market Forecast 2017-2029

7.6.2 Chinese Asthma and COPD Therapies Market: Trends and Developments

7.6.2.1 China’s Industrial Future and Asthma/COPD

7.6.2.2 Expansion of Healthcare Coverage and Reimbursement

7.6.2.3 Price Controls and the Anhui Model

7.6.3 Brazilian Asthma and COPD Therapies Market Forecast 2017-2029

7.6.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments

7.6.4.1 Increasing Access to Medicines

7.6.5 Indian Asthma and COPD Therapies Market Forecast 2017-2029

7.6.6 Indian Asthma and COPD Therapies Market: Trends and Developments

7.6.6.1 Drug Prices Control Order 2013

7.6.6.2 Expansion of Healthcare Provision

7.6.7 Russian Asthma and COPD Therapies Market Forecast 2017-2029

7.6.8 Russian Asthma and COPD Therapies Market: Trends and Developments

7.6.8.1 No Embargo on Foreign Drug Imports

7.6.8.2 Pharma2021 and the Russian Pharmaceutical Industry

7.7 Mexican Asthma and COPD Therapies Market 2017-2029

7.7.1 Mexican Asthma and COPD Therapies Market Forecast 2017-2029

7.7.2 Mexican Asthma and COPD Therapies Market: Trends and Developments

7.7.2.1 Seguro Popular: Mexican Healthcare Reform

7.7.2.2 COFEPRIS: Regulatory Changes and Improvements

7.7.2.3 Mexico’s Agreement for Innovation

8. Leading Companies in the Asthma and COPD Therapies Market

8.1 Asthma and COPD Therapies: Increasing Competition

8.2 Leading Companies in Asthma and COPD in 2017

8.3 Leading Companies: Market Forecast 2017-2029

8.4 How Will Leading Companies’ Market Shares Change to 2029?

8.5 GSK

8.5.1 GSK: Asthma and COPD Therapies

8.5.2 GSK: Sales Forecast 2017-2029

8.5.3 GSK: Products in Development

8.5.4 GSK: Recent Developments

8.5.4.1 Recently Launched Combination Drugs

8.5.4.2 GSK Divests OTC Products

8.5.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health

8.5.4.4 GSK Presents Data on Eosinophil Levels and COPD

8.6 Boehringer Ingelheim

8.6.1 Boehringer Ingelheim: Asthma and COPD Therapies

8.6.2 Boehringer Ingelheim: Sales Forecast 2017-2029

8.6.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased

8.6.4 Boehringer Ingelheim: Recent Developments

8.6.4.1 Expansion of Respimat Manufacturing Capacity

8.6.4.2 Respimat Safety Concerns and the TIOSPIR Study

8.6.4.3 Ben Venue Laboratories Shut Down

8.6.4.4 Sale of Roxane Laboratories

8.6.4.5 Spiloto Respimat and the PHYSACTO Study

8.7 AstraZeneca

8.7.1 AstraZeneca: Asthma and COPD Therapies

8.7.2 AstraZeneca: Sales Forecast 2017-2029

8.7.3 AstraZeneca: Products in Development

8.7.4 AstraZeneca: Recent Developments

8.7.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio

8.7.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline

8.7.4.3 AstraZeneca Rejects Pfizer Takeover Bid

8.7.4.4 AstraZeneca Acquires Right to Actavis’ Branded Respiratory Portfolio in US and Canada

8.7.4.5 Takeda Respiratory Portfolio Acquisition

8.8 Merck & Co. (Merck)

8.8.1 Merck: Asthma and COPD Therapies

8.8.2 Merck: Sales Forecast 2017-2029

8.8.3 Merck: Products in Development

8.8.4 Merck: Recent Developments

8.8.4.1 Bayer Acquires Merck’s Consumer Health Business

8.8.4.2 FDA Rejects Singulair OTC Switch

8.8.4.3 Takeda Ended Co-Promotion of Daxas with Merck

8.9 Novartis

8.9.1 Novartis: Asthma and COPD Therapies

8.9.2 Novartis: Sales Forecast 2017-2029

8.9.3 Novartis: Products in Development

8.9.4 Novartis: Recent Developments

8.9.4.1 Novartis Restructures Following Strategic Review

8.9.4.2 Novartis Presents Data on Ultibro and Seebri

8.9.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK

8.10 Roche

8.10.1 Roche: Asthma and COPD Therapies

8.10.2 Roche: Sales Forecast 2017-2029

8.10.3 Roche: Products in Development

8.11 Teva

8.11.1 Teva: Asthma and COPD Therapies

8.11.2 Teva: Sales Forecast 2017-2029

8.11.3 Teva: Products in Development

8.11.4 Teva: Recent Developments

8.11.4.1 Launch of DuoResp Spiromax

9. Asthma and COPD Therapies Pipeline Analysis 2017-2029

9.1 A Strong Asthma and COPD Pipeline

9.2 The Bronchodilators Pipeline

9.2.1 Bronchodilators: Phase 3 Pipeline

9.2.1.1 AZD8871 (MABA, AstraZeneca)

9.2.1.2 GSK961081 (Batefenterol, GSK)

9.2.1.3 LAS100977 (Abediterol, AstraZeneca)

9.2.1.4 QVAR BAI (beclometasone, Teva)

9.3 The Anti-Inflammatory Drugs Pipeline

9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline

9.3.1.1 mepolizumab (IL-5 receptor antagonist, GSK)

9.3.1.2 benralizumab (IL-5 receptor antagonist, AstraZeneca)

9.3.1.3 tralokinumab (IL-13 receptor antagonist, AstraZeneca)

9.3.1.4 QAW039 (fevipiprant, Novartis)

9.3.1.5 Lebrikizumab (IL-13 receptor antagonist, Roche)

9.4 The Combination Drugs Pipeline

9.4.1 Combination Drugs: Phase 3 Pipeline

9.4.1.1 fluticasone furoate & vilanterol & umeclidinium (GSK)

9.4.1.2 PT010 (long-acting muscarinic antagonist (LAMA) glycopyrronium, the long acting β2-agonist (LABA) formoterol fumarate and budesonide, an inhaled corticosteroid (ICS), AstraZeneca)

9.4.1.3 QMF149 (indacaterol, mometasone furoate, Novartis)

9.4.1.4 QVM149 (indacaterol, glycopyrronium, mometasone, Novartis)

9.5 Other Asthma and COPD Drugs Pipeline

10. Qualitative Analysis of the Asthma and COPD Therapies Market 2017-2029

10.1 SWOT Analysis of the Asthma and COPD Therapies Market

10.2 Strengths

10.2.1 Increasing Prevalence and Disease Burden

10.2.2 High Costs of Treatment

10.2.3 The Changing Perception of COPD

10.2.4 Patient Education: Understanding the Severity of Respiratory Disease

10.2.5 Lifecycle Management Strategies to Counter Patent Expiry

10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion

10.2.7 Developments in Diagnostics

10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD

10.2.7.2 Biological Markers in COPD

10.3 Weaknesses

10.3.1 Under-Diagnosis: the ‘Ghost Population’

10.3.2 Side-Effects of Drug Classes

10.3.3 Patent Cliff for Devices

10.3.4 Low Patient Adherence

10.3.5 Costing Pressures in both Developed and Emerging Markets

10.4 Opportunities

10.4.1 Patient Phenotyping and Personalised Medicine

10.4.2 A Strong R&D Pipeline

10.4.3 Ultra-Long-Acting Beta2-Agonists

10.4.4 Muscarinic Antagonists and Beta2-Agonists (MABAs)

10.4.5 Monoclonal Antibodies

10.4.6 LAMA/LABA Combinations

10.4.7 Opportunities in Telehealth

10.5 Threats

10.5.1 Patent Expiry and Generic Competition

10.5.2 Pharmacy Benefit Managers and Cost Control

10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD

10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market

10.6.1 Rivalry among Competitors [Medium]

10.6.2 Threat of New Entrants [Medium]

10.6.3 Power of Suppliers [Medium]

10.6.4 Power of Buyers [High]

10.6.5 Threat of Substitutes [Low]

11. Conclusions

11.1 Asthma and COPD Therapies: A Maturing Market

11.2 The Global Asthma and COPD Therapies Market in 2017

11.3 Current Leading Asthma and COPD Therapies Segments

11.3.1 Leading Asthma and COPD Therapies

11.3.2 Leading Asthma and COPD Therapies Companies

11.4 Leading Regional and National Markets

11.5 Global Asthma and COPD Therapies Market Forecast 2017-2029

11.6 The Future of the Asthma and COPD Therapies Market

11.6.1 Growth in Anti-Inflammatory and Combination Drugs

11.6.2 Personalised Medicine

11.6.3 Unmet Needs in Asthma and COPD

11.7 Strategies for Growth in 2017-2029

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

Appendix A

About Visiongain

Appendix B

Visiongain report evaluation form

List of Tables

Table 2.1 Classification of Respiratory Diseases, 2018

Table 2.2 Causes of Asthma, 2018

Table 2.3 Triggers of Asthma, 2018

Table 2.4 Clinical Trial Phases

Table 3.1 Global Asthma & COPD Market: Revenues ($m) and Market Shares (%) by Therapeutic Area, 2018

Table 3.2 Top 10 Asthma and COPD Therapies: Revenue ($m) and Market Shares (%), 2017

Table 3.3 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 3.4 World Asthma Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 3.5 World COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 3.6 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029

Table 3.7 Market Shares (%) of Leading Asthma and COPD Therapies Market Segments, by Drug Class, 2018, 2023 and 2029

Table 4.1 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2018

Table 4.2 Leading Bronchodilators: Revenues ($m) and Market Shares (%), 2017

Table 4.3 Bronchodilator Monotherapy Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029

Table 4.4 Leading Anticholinergics: Revenues ($m) and Market Shares (%), 2017

Table 4.5 Anticholinergics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029

Table 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2018, 2023 and 2029

Table 4.7 Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.8 Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.9 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.10 Leading SABAs in 2017

Table 4.11 SABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029

Table 4.12 SABAs Market: Market Shares (%) by Drug, 2017, 2023 and 2029

Table 4.13 GSK: Ventolin Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.14 Teva: ProAir Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.15 Merck: Proventil Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.16 Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.17 Leading LABAs: Revenues ($m) and Market Shares (%), 2017

Table 4.18 LABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029

Table 4.19 Leading LABAs: Market Shares (%) by Drug, 2017, 2023 and 2029

Table 4.20 Merck/Novartis: Foradil Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.21 Dainippon Sumitomo: Brovana Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.22 Novartis: Arcapta/Onbrez Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 4.23 GSK: Serevent Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2017

Table 5.2 Leading Anti-Inflammatory Drugs: Revenues ($m) and Market Shares (%), 2017

Table 5.3 Anti-Inflammatory Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029

Table 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2023 and 2029

Table 5.5 Leading Corticosteroids: Revenues ($m) and Market Shares (%), 2017

Table 5.6 Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029

Table 5.7 Corticosteroids Market: Market Share (%) by Drug, 2017, 2023 and 2029

Table 5.8 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2017-2029

Table 5.9 AstraZeneca: Pulmicort Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 5.10 Teva: QVAR Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 5.11 Merck: Asmanex Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 5.12 Leading Anti-Leukotrienes: Revenues ($m) and Market Shares (%), 2017

Table 5.13 Anti-Leukotrienes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029

Table 5.14 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2017, 2023 and 2029

Table 5.15 Merck: Singulair Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 5.16 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029

Table 5.17 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2017, 2023 and 2029

Table 5.18 Novartis/Roche: Xolair Asthma Indication Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 5.19 Teva: Cinquil/Cinquair Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 5.20 GSK: Nucala Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 5.21 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 5.22 Roche: Lebrikizumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 5.23 Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 6.1 Leading Combination Drugs: Revenues ($m) and Market Share (%), 2017

Table 6.2 Combination Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029

Table 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2017, 2023 and 2029

Table 6.4 GSK: Advair/Seretide Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 6.5 AstraZeneca: Symbicort Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 6.6 Boehringer Ingelheim: Combivent Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 6.7 Merck: Dulera Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 6.8 GSK: Relvar/Breo Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 7.1 Global Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2017

Table 7.2 Global Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2017-2029

Table 7.3 Leading Regional Asthma and COPD Therapies Market: Market Share (%) 2018, 2023 and 2029

Table 7.4 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by National Market, 2018

Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029

Table 7.6 Market Shares (%) of Leading National Asthma and COPD Therapies Markets, 2018, 2023 and 2029

Table 7.7 US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029

Table 7.8 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029

Table 7.9 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029

Table 7.10 German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027

Table 7.11 French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029

Table 7.12 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029

Table 7.13 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029

Table 7.14 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029

Table 7.15 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029

Table 7.16 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029

Table 7.17 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029

Table 7.18 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029

Table 7.19 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029

Table 7.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029

Table 8.1 Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue ($m), Market Share (%), 2017

Table 8.2 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2017-2029

Table 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m) and Market Shares (%), 2017, 2023 and 2029

Table 8.4 GSK: Overview

Table 8.5 GSK: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017

Table 8.6 GSK: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029

Table 8.7 GSK: Asthma and COPD Therapies Pipeline

Table 8.8 Boehringer Ingelheim: Overview

Table 8.9 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017

Table 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2017-2029

Table 8.11 AstraZeneca: Overview

Table 8.12 AstraZeneca: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017

Table 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2017-2029

Table 8.14 AstraZeneca: Asthma and COPD Therapies Pipeline

Table 8.15 Merck: Overview

Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017

Table 8.17 Merck: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029

Table 8.18 Novartis: Overview

Table 8.19 Novartis: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017

Table 8.20 Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029

Table 8.21 Novartis: Asthma and COPD Therapies Pipeline

Table 8.22 Roche: Overview

Table 8.23 Roche: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029

Table 8.24 Teva: Overview

Table 8.25 Teva: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017

Table 8.26 Teva: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029

Table 8.27 Teva: Asthma and COPD Therapies Pipeline



List of Figures

Figure 1.1 Global Asthma and COPD Therapies Market Segmentation Overview, 2018

Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2018

Figure 2.2 Summary of GOLD Guidance for COPD Treatment, 2018

Figure 3.1 World Respiratory Drugs Market: Revenues ($m) by Therapeutic Area, 2018

Figure 3.2 World Respiratory Drugs Market: Market Shares (%) by Therapeutic Area, 2018

Figure 3.3 Top 10 Asthma and COPD Therapies: Market Shares (%), 2017

Figure 3.4 World Asthma and COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 3.5 World Asthma Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 3.6 World COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 3.7 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2018

Figure 3.8 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2023

Figure 3.9 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2029

Figure 3.10 World Asthma and COPD Therapies Market: Drivers and Restraints, 2017-2029

Figure 4.1 Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2018

Figure 4.2 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2023

Figure 4.3 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2029

Figure 4.4 Bronchodilator Monotherapy Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 4.5 Anticholinergics Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2018

Figure 4.7 Anticholinergics Market: Market Shares (%) by Drug, 2023

Figure 4.8 Anticholinergics Market: Market Shares (%) by Drug, 2029

Figure 4.9 Boehringer Ingelheim: Spiriva Revenue ($m) and AGR (%), 2017-2029

Figure 4.10 Boehringer Ingelheim: Atrovent Revenue ($m) and AGR (%), 2017-2029

Figure 4.11 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m) and AGR (%), 2017-2029

Figure 4.12 SABAs Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 4.13 SABAs Market: Market Shares (%) by Drug, 2018

Figure 4.14 SABAs Market: Market Shares (%) by Drug, 2023

Figure 4.15 SABAs Market: Market Shares (%) by Drug, 2029

Figure 4.16 GSK: Ventolin Revenue ($m) and AGR (%), 2017-2029

Figure 4.17 Teva: ProAir Revenue ($m) and AGR (%), 2017-2029

Figure 4.18 Merck: Proventil Revenue ($m) and AGR (%), 2017-2029

Figure 4.19 Dainippon Sumitomo: Xopenex Revenue ($m) and AGR (%), 2017-2029

Figure 4.20 LABAs Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 4.21 LABAs Market: Market Shares (%) by Drug, 2018

Figure 4.22 LABAs Market: Market Shares (%) by Drug, 2023

Figure 4.23 LABAs Market: Market Shares (%) by Drug, 2029

Figure 4.24 Merck/Novartis: Foradil Revenue ($m) and AGR (%), 2017-2029

Figure 4.25 Dainippon Sumitomo: Brovana Revenue ($m) and AGR (%), 2017-2029

Figure 4.26 Novartis: Arcapta/Onbrez Revenue ($m) and AGR (%), 2017-2029

Figure 4.27 GSK: Serevent Revenue ($m) and AGR (%), 2017-2029

Figure 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2017

Figure 5.2 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2017

Figure 5.3 Anti-Inflammatory Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2023

Figure 5.5 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2023

Figure 5.6 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2029

Figure 5.7 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2029

Figure 5.8 Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 5.9 Corticosteroids Market: Market Share (%) by Drug, 2017

Figure 5.10 Corticosteroids Market: Market Share (%) by Drug, 2023

Figure 5.11 Corticosteroids Market: Market Share (%) by Drug, 2029

Figure 5.12 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2017-2029

Figure 5.13 AstraZeneca: Pulmicort Revenue ($m) and AGR (%), 2017-2029

Figure 5.14 Teva: QVAR Revenue ($m) and AGR (%), 2017-2029

Figure 5.15 Merck: Asmanex Revenue ($m) and AGR (%), 2017-2029

Figure 5.16 Anti-Leukotrienes Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 5.17 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2018

Figure 5.18 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2023

Figure 5.19 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2029

Figure 5.20 Merck: Singulair Revenue ($m) and AGR (%), 2017-2029

Figure 5.21 Monoclonal Antibodies Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 5.22 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2017

Figure 5.23 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2023

Figure 5.24 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2029

Figure 5.25 Novartis/Roche: Xolair Asthma Indication Revenue ($m) and AGR (%), 2017-2029

Figure 5.26 Teva: Cinquil/Cinquair Revenue ($m) and AGR (%), 2017-2029

Figure 5.27 GSK: Nucala Revenue ($m) and AGR (%), 2017-2029

Figure 5.28 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m) and AGR (%), 2017-2029

Figure 5.29 Roche: Lebrikizumab Revenue ($m) and AGR (%), 2017-2029

Figure 5.30 Regeneron/Sanofi: Dupilumab Revenue ($m) and AGR (%), 2017-2029

Figure 6.1 Combination Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2029

Figure 6.2 Combination Drugs Market: Market Shares (%) by Drug, 2017

Figure 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2023

Figure 6.4 Combination Drugs Market: Market Shares (%) by Drug, 2029

Figure 6.5 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2017-2029

Figure 6.6 AstraZeneca: Symbicort Revenue ($m) and AGR (%), 2017-2029

Figure 6.7 Boehringer Ingelheim: Combivent Revenue ($m) and AGR (%), 2017-2029

Figure 6.8 Merck: Dulera Revenue ($m) and AGR (%), 2017-2029

Figure 6.9 GSK: Relvar/Breo Revenue ($m) and AGR (%), 2017-2029

Figure 7.1 Global Asthma and COPD Therapies Market: Revenues ($m) by Region, 2017

Figure 7.2 Global Asthma and COPD Therapies Market: Market Shares (%) by Region, 2017

Figure 7.3 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Region, 2017-2029

Figure 7.4 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2023

Figure 7.5 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2029

Figure 7.6 World Asthma and COPD Therapies Market: Revenues ($m) by National Market, 2018

Figure 7.7 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2018

Figure 7.8 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2023

Figure 7.9 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2029

Figure 7.10 US Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029

Figure 7.11 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029

Figure 7.12 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2017-2029

Figure 7.13 German Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029

Figure 7.14 French Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029

Figure 7.15 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and 2017-2029

Figure 7.16 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029

Figure 7.17 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029

Figure 7.18 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2017-2029

Figure 7.19 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029

Figure 7.20 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029

Figure 7.21 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027

Figure 7.22 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029

Figure 7.23 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029

Figure 8.1 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), 2017

Figure 8.2 Leading Asthma and COPD Drug Manufacturers: Market Share (%), 2017

Figure 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2023

Figure 8.4 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2023

Figure 8.5 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2029

Figure 8.6 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2029

Figure 8.7 GSK: Asthma and COPD Therapies Revenue ($m) by Drug, 2017

Figure 8.8 GSK: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017

Figure 8.9 GSK: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029

Figure 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) by Drug, 2017

Figure 8.11 Boehringer Ingelheim: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017

Figure 8.12 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029

Figure 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m) by Drug, 2017

Figure 8.14 AstraZeneca: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017

Figure 8.15 AstraZeneca: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029

Figure 8.16 Merck: Asthma and COPD Therapies Revenue ($m) by Drug, 2017

Figure 8.17 Merck: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017

Figure 8.18 Merck: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029

Figure 8.19 Novartis: Asthma and COPD Therapies Revenue ($m) by Drug, 2017

Figure 8.20 Novartis: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017

Figure 8.21 Novartis: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029

Figure 8.22 Roche: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029

Figure 8.23 Teva: Asthma and COPD Therapies Revenue ($m) by Drug, 2017

Figure 8.24 Teva: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017

Figure 8.25 Teva: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029

Figure 10.1 Asthma and COPD Therapies Market: Strengths and Weaknesses, 2017-2029

Figure 10.2 Asthma and COPD Therapies Market: Opportunities and Threats, 2017-20279

Figure 10.3 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market, 2017-2029

Figure 12.1 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Therapeutic Area, 2017-2029